Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Gastroenterology|October 9, 2019
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic EsophagitisIkuo Hirano, Evan S Dellon, Jennifer D Hamilton, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 1, 2020
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitisWilliam W Busse, Jorge F Maspero, Yufang Lu, et al.
JAMA Dermatology|December 27, 2019
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical TrialMargitta Worm, Eric L Simpson, Diamant Thaçi, et al.
The New England Journal of Medicine|October 4, 2016
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisEric L Simpson, Thomas Bieber, Emma Guttman-Yassky, et al.
Rhinology|April 13, 2021
Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNPM Desrosiers, L P Mannent, N Amin, et al.
Journal of the American Academy of Dermatology|June 24, 2020
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S Paller, Elaine C Siegfried, Diamant Thaçi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 28, 2019
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic RhinosinusitisJorge F Maspero, Constance H Katelaris, William W Busse, et al.
The New England Journal of Medicine|May 22, 2018
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaMario Castro, Jonathan Corren, Ian D Pavord, et al.
The British Journal of Dermatology|March 10, 2019
Conjunctivitis in dupilumab clinical trialsB Akinlade, E Guttman-Yassky, M de Bruin-Weller, et al.
Journal of the American Academy of Dermatology|August 3, 2019
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension studyMette Deleuran, Diamant Thaçi, Lisa A Beck, et al.
Pageof 8